After Piper Jaffray and Mizuho Securities gave Nektar Therapeutics (NASDAQ: NKTR) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Andy Hsieh assigned a Buy rating to Nektar Therapeutics yesterday. The company’s shares closed yesterday at $32.92, close to its 52-week low of $29.22.
According to TipRanks.com, Hsieh is a 1-star analyst with an average return of -1.9% and a 35.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Seattle Genetics, and ImmunoGen.
Nektar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $77.50, representing a 135.4% upside. In a report issued on May 24, Mizuho Securities also reiterated a Buy rating on the stock with a $81 price target.
See today’s analyst top recommended stocks >>
Nektar Therapeutics’ market cap is currently $5.74B and has a P/E ratio of 9.34. The company has a Price to Book ratio of 3.51.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NKTR in relation to earlier this year. Most recently, in March 2019, Scott R. Greer, a Director at NKTR bought 10,000 shares for a total of $51,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments.
